Back to Search Start Over

Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile

Authors :
Mauro, Fr
Molica, S
Laurenti, Luca
Cortelezzi, A
Carella, Am
Zaja, F
Chiarenza, A
Angrilli, F
Nobile, F
Marasca, R
Musolino, C
Brugiatelli, M
Piciocchi, A
Vignetti, M
Fazi, P
Gentile, G
De Propris, M
Starza, Id
Marinelli, M
Chiaretti, S
Del Giudice, I
Nanni, M
Albano, F
Cuneo, A
Guarini, A
Foà, R.
Laurenti, Luca (ORCID:0000-0002-8327-1396)
Mauro, Fr
Molica, S
Laurenti, Luca
Cortelezzi, A
Carella, Am
Zaja, F
Chiarenza, A
Angrilli, F
Nobile, F
Marasca, R
Musolino, C
Brugiatelli, M
Piciocchi, A
Vignetti, M
Fazi, P
Gentile, G
De Propris, M
Starza, Id
Marinelli, M
Chiaretti, S
Del Giudice, I
Nanni, M
Albano, F
Cuneo, A
Guarini, A
Foà, R.
Laurenti, Luca (ORCID:0000-0002-8327-1396)
Publication Year :
2014

Abstract

In 45, ≤60 years old patients with CLL and an adverse biologic profile, a front-line treatment with Fludarabine and Campath (Alemtuzumab(®)) was given. The overall response rate was 75.5%, the complete response rate (CR) 24.4% with the lowest CR rates, 16.7% and 8.3%, in 11q and 17p deleted cases. The 3-year progression-free survival (PFS) and overall survival were 42.5% and 79.9%, respectively. PFS was significantly influenced by CLL duration, beta2-microglobulin, and improved by post-remissional stem cell transplantation. Front-line fludarabine and alemtuzumab showed a manageable safety profile and evidence of a benefit in a small series of CLL patients with adverse biologic features.

Details

Database :
OAIster
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1105015901
Document Type :
Electronic Resource